VEGFA antibody

Catalog No. ABIN1589696

Product Details anti-VEGFA Antibody

Target: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This VEGFA antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Purpose: VEGF-A antibody

Specificity: Recombinant human VEGF189 protein

Characteristics: Chromosomal location: 6p12
Monoclonals were produced with the help of BALB/c mice using recombinant human VEGF189 (42 kDa) as the immunizing antigen.

Purification: Mouse IgG1 antibody (clone 339/H2) from hybridomas was purified from cell culture supernatant by Protein A/G chromatography.

Immunogen: Recombinant human VEGF189 protein (ABIN1589577 and ABIN1589579)

Clone: 339-H2

Isotype: IgG1

Application Details

Application Notes: ELISA: Use at 1-15 μg/mL. Western blotting: Use at 1-2 μg/mL.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Handling Advice: Centrifuge vial prior to opening.

Storage: 4 °C,-20 °C

Storage Comment: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Expiry Date: 24 months

Target Details for VEGFA

Target: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Alternative Name: VEGF-A (VEGFA Products)

Background: VEGFA, VPF, VEGF, MVCD1,Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53 % amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Gene ID: 7422

NCBI Accession: NM_001171626, NP_001165097

UniProt: P15692

Pathways: RTK Signaling, Glycosaminoglycan Metabolic Process, Regulation of Cell Size, Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling